Bifidobacterium breve M-16V and Reduced All-Cause Mortality

• Benefits of Bifidobacterium breve M-16V Supplementation in Preterm Neonates - A Retrospective Cohort Study

  • 2016-03-08
  • Meta-Analysis
  • PLOS ONE 11(3)
  • • S. Patole
    • Shripada C Rao
    • A. Keil
    • E. Nathan
    • D. Doherty
    • K. Simmer

  • PubMed: 26953798
  • DOI: 10.1371/journal.pone.0150775

  4 Insights on

  • Reduced All-Cause Mortality

  • High evidence
  • Highly Cited
  • Rigorous Journal

  all-cause mortality: 7% vs. 4%, aOR = 0.58 (95% CI: 0.31-1.06)

  Effect

  Beneficial

  Effect size

  Small

  Significant

  No